[{"data":1,"prerenderedAt":153},["ShallowReactive",2],{"drug-vibegron":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":35,"contraindications":58,"warnings":68,"renal":76,"monitoring":77,"interactions":78,"review":79,"examples":82,"atc":88,"iran":90,"usApproval":97,"links":103,"populations":117},"vibegron",1,{"fa":7,"en":8},"ویبگرون","Vibegron","genitourinary-sex-hormones",{"fa":11,"en":12},"آگونیست بتا-۳","Beta-3 adrenergic agonist",[14],{"name":15,"market":16},"Gemtesa","US",[18,19,7],"gemtesa","جمتسا",[21],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":30,"refs":31},"tab-75","tablet","oral","75 mg tablet",{"amount":27,"unit":28,"perUnit":23,"scored":29},75,"mg",false,[16],[32],{"source":33,"section":34},"fda-gemtesa","3",[36],{"id":37,"disease":38,"label":39,"population":42,"type":46,"unit":28,"dose":47,"refs":48,"notes":51},"oab","overactive-bladder",{"fa":40,"en":41},"مثانه بیش‌فعال بزرگسال — ۷۵ mg یک بار","Overactive bladder, adults — 75 mg once daily",{"minAge":43},{"value":44,"unit":45},18,"year","fixed",{"perDose":27,"dosesPerDay":5},[49],{"source":33,"section":50},"2.1",[52],{"text":53,"refs":56},{"fa":54,"en":55},"با یا بدون غذا؛ در بزرگسال می‌توان خرد کرد و با پوره سیب داد.","With or without food; in adults may be crushed into applesauce.",[57],{"source":33,"section":50},[59],{"id":60,"severity":61,"text":62,"refs":65},"hyper","block",{"fa":63,"en":64},"حساسیت به ویبگرون (آنژیوادم).","Hypersensitivity to vibegron (angioedema).",[66],{"source":33,"section":67},"4",[69],{"text":70,"refs":73},{"fa":71,"en":72},"احتباس ادرار (به‌ویژه با انسداد خروجی یا همراه آنتی‌موسکارینی)؛ آنژیوادم.","Urinary retention (especially with outlet obstruction or with antimuscarinics); angioedema.",[74],{"source":33,"section":75},"5",[],[],[],{"status":80,"reviewer":81,"date":81},"unverified",null,[83],{"regimen":37,"formulation":22,"input":84,"expect":87},{"ageYears":85,"weightKg":86},60,70,{"perDose":27,"tabletsPerDoseRounded":5},[89],"G04BD15",{"status":91,"refs":92},"not-found",[93],{"source":94,"section":95,"url":96},"darooyab-generic","search","https:\u002F\u002Fwww.darooyab.ir\u002FSearch?q=Vibegron",{"kind":98,"refs":99,"id":102},"NDA",[100],{"source":33,"section":101},"SPL approval \u002F marketing category","NDA213006",[104,107,111,114],{"kind":105,"url":106,"label":102},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=213006",{"kind":108,"url":109,"label":110},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=25f21d25-14f8-4fda-91f6-7aa8b68aa1c8","FDA Gemtesa",{"kind":112,"url":113,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa621015.html",{"kind":115,"url":116,"label":89},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=G04BD15",{"pregnancy":118,"lactation":127,"pediatric":135,"geriatric":144},{"level":119,"text":120,"quote":123,"refs":124},"caution",{"fa":121,"en":122},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary There are no available data on GEMTESA use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.",[125],{"source":33,"section":126},"8.1",{"level":119,"text":128,"quote":131,"refs":132},{"fa":129,"en":130},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary There are no data on the presence of vibegron in human milk, the effects of the drug on the breastfed infant, or the effects on milk production.",[133],{"source":33,"section":134},"8.2",{"level":136,"text":137,"quote":140,"refs":141},"not-established",{"fa":138,"en":139},"برچسب: ایمنی و اثربخشی در کودکان ثابت نشده است.","Label: safety and effectiveness in children have not been established.","The safety and effectiveness of GEMTESA in pediatric patients have not been established.",[142],{"source":33,"section":143},"8.4",{"level":145,"text":146,"quote":149,"refs":150},"ok",{"fa":147,"en":148},"برچسب: در سالمندان تفاوت یا تنظیم دوز خاصی ذکر نشده.","Label: no specific difference or dose adjustment stated for older adults.","No overall differences in safety or effectiveness of GEMTESA have been observed between patients 65 years of age and older and younger adult patients.",[151],{"source":33,"section":152},"8.5",1792191572558]